Platform Comparison Guide · Updated October 2026

USVC vs Fundrise VCX 2026

Two registered venture funds that any US investor can buy, holding overlapping private technology positions through the same kind of special purpose vehicles. One issues its own shares at net asset value. The other trades on the NYSE, and has traded well above it. This guide compares them from the filings: audited annual reports, quarterly holdings, the at-the-market prospectus supplement, and both tender offers.

Guide Thesis

Similar portfolios. Very different entry prices.

VCX: $776.97M net assets, 2.57% audited expense ratio, daily NYSE liquidity, and a $38.12 close against a $21.70 NAV on September 8, 2026. USVC: $500 minimum, shares issued at NAV, 2.50% net expenses under a waiver to November 2027, and an exit the board may decline to offer.

Most comparisons of these two argue about fees. The running-cost figures converge near 2.5%, and they are not measured the same way.

What differs is the price of admission. On September 8, 2026, $10,000 bought about $5,693 of VCX portfolio and $10,000 of USVC portfolio.

USVC vs Fundrise Innovation Fund VCX comparison 2026

The Core Decision

You are choosing a pricing mechanism, not an asset class.

Both funds hold private technology companies through third-party vehicles, and both disclose exposure to Anthropic and OpenAI, although only VCX publishes the size of those economic exposures. VCX gives you a bigger, older, better-documented portfolio and the ability to sell on any trading day, at whatever premium or discount the market is paying. USVC gives you the same asset class at net asset value, with no market to sell into and a repurchase offer the board is not required to make.

Buys at NAV

USVC

New shares are issued by the fund at the next calculated NAV, $22.47 on September 29, 2026, with no sales load on usvc.com and a $500 minimum. VCX shares are bought from other investors at the market price.

Lower Running Cost

VCX

An audited 2.57% gross expense ratio for the year ended March 31, 2026, with no waiver required, against USVC's forward estimate of 4.55% reduced to 2.50% net by a waiver that ends November 24, 2027.

Sells Any Trading Day

VCX

Daily NYSE liquidity at the prevailing price. USVC's only exit is a quarterly tender offer the board may decline; the first one repurchased 1.1% of net assets.

TL;DR

The comparison in two paragraphs

VCX is older, larger, exchange-traded and better documented, and USVC's structural advantage is a different one: investors buy at NAV rather than at whatever premium the secondary market assigns. The Innovation Fund held $776.97 million at June 30, 2026 across 62 positions, reported a 68.39% NAV return for the year ended March 31, 2026 and 19.45% annualized since its July 2022 inception, runs at an audited 2.57% expense ratio, is audited by KPMG, names its economic issuers in its annual report, and trades on the NYSE every day. Its problem is what the market charges for that: a $38.12 close against a $21.70 NAV on September 8, 2026, which the fund itself discloses on the cover of a prospectus supplement that warns premium buyers may lose money even if NAV rises.

USVC is five audited months old, held $39.35 million at the same date with 39.0% of it in a money market fund, and spent its first fiscal year 92% owned by its own adviser. It costs about the same to run, 2.50% while a waiver holds to November 2027, against a 4.55% gross estimate. What it offers is the absence of a premium: the fund issues shares at NAV and repurchases them at NAV, when it chooses to.

If you read nothing else: scroll to the head-to-head comparison sections →

VCX suits you if

  • → You want to be able to sell on any trading day
  • → You want a three-year record and a KPMG opinion behind it
  • → You want the economic issuers named and sized in the filings
  • → You can judge, and accept, the premium you pay on the day you buy

USVC suits you if

  • → You will not pay more than net asset value for a Level 3 portfolio
  • → You are starting small; the minimum is $500 with no load direct
  • → You can hold through quarters with no repurchase offer at all
  • → You would rather own the AngelList network's deal flow than Fundrise's

75.7%

VCX premium to NAV, September 8, 2026

A $38.12 close against a $21.70 NAV, both on the cover of the fund's own prospectus supplement. The shares first traded at $31.25 on March 19, 2026 and the audited NAV at March 31 was $18.97, twelve days apart, so no first-day premium can be computed from that pair.

22.3%

VCX price decline, September 8 to 30

$38.12 to $29.62 in three weeks, with no filing reporting a NAV move of that size. The lockup expired August 14 and a $1 billion at-the-market program began September 10.

1.1%

USVC repurchased in its first tender

19,379.119 shares at $22.04, about $427,000, against a $2 million cap and a stated intention of up to 5% of net assets per quarter. The board may decline to make an offer.

Bottom Line Up Front

On the portfolio, the record and the disclosure, the Fundrise Innovation Fund is the more established of the two. Three years of audited operations, $776.97 million of net assets, 62 positions, a top-ten table that names Anthropic, Databricks and OpenAI with their weights, a KPMG opinion, and a 2.57% expense ratio that needs no waiver to get there. USVC cannot match any of that yet, and its own prospectus says the adviser had no prior registered-fund experience.

On the price of entry, it is not close. A listed closed-end fund is worth what the market pays, and the market has paid a large premium for VCX through the listing period, including the 75.7% the fund itself reported for September 8. The fund discloses the gap itself and warns about it in the plainest language a prospectus uses. USVC sells at NAV, which removes that risk entirely and replaces it with a different one: there may be no way out for a quarter or more, because the repurchase offer is discretionary.

The mistake to avoid differs on each side. With VCX, do not treat the market price as evidence about the portfolio; check the premium before you buy and remember you will sell at whatever premium exists then. With USVC, do not treat the 2.50% expense ratio or the tender offer as commitments; the waiver expires in November 2027 and the offers are the board's to make or skip.

Head to Head

USVC vs Fundrise VCX, section by section

The same wrapper, two ways of selling it

USVC vs VCX: Structure

These two funds are closer in legal form than almost any other pair AltStreet compares. Both are non-diversified closed-end management investment companies registered under the Investment Company Act of 1940, both are Delaware entities open to any US investor with a tax identification number, both reach private technology companies through a mixture of third-party special purpose vehicles and direct positions, and both file audited annual reports and quarterly holdings on EDGAR. The divergence is entirely in distribution. The Fundrise Innovation Fund spent three and a half years as a tender offer fund, then listed: shareholders approved the conversion on February 19, 2026 and the shares began trading on the NYSE as VCX on March 19, 2026 at $31.25. USVC does what the Innovation Fund used to do, continuously issuing its own shares at NAV and buying them back only when its board offers to.

Legal formBoth: non-diversified closed-end management investment companies registered under the 1940 Act. VCX: Fundrise Innovation Fund, LLC, a Delaware LLC, CIK 1867090, Commission File 001-43180, formerly Fundrise Growth Tech Fund, LLC until January 20, 2026. USVC: USVC Venture Capital Access Fund, a Delaware statutory trust, CIK 1858660, SEC file 811-23660.
How shares are pricedVCX: on the NYSE, by the market. The fund's September 10, 2026 prospectus supplement reports a September 8 close of $38.12 against a NAV of $21.70. USVC: at the next calculated NAV, $22.47 on September 29, 2026, with no load on usvc.com and up to 3% through intermediaries.
Age and scaleVCX: commenced investment operations July 25, 2022; net assets $776,968,362 at June 30, 2026. USVC: commenced November 3, 2025; net assets $39,348,007 at the same date, and about $55,767,986 of capital outstanding at September 25, 2026.
AdviserVCX: Fundrise Advisors, LLC, an SEC-registered adviser to a platform reporting roughly $3.4 billion of assets and more than 402,000 investor accounts. USVC: AngelList Asset Management, LLC, formed in December 2023, which its own prospectus says "has no previous experience managing a closed-end, registered investment company" and which held about 20% of the fund's shares at September 25, 2026.
Audit and service providersVCX: KPMG LLP, which states it has served as auditor of one or more Fundrise investment companies since 2019. USVC: RSM US LLP, with Trailmark Fund Solutions as administrator and transfer agent since April 28, 2026 and U.S. Bank as custodian.

Verdict

Choose on the pricing mechanism, because everything else about these two is a difference of degree. A listed fund hands price discovery to the market, for better and worse. A continuously offered fund hands it to the adviser's valuation process and makes the exit a matter of board discretion.

The number that decides this comparison

USVC NAV vs VCX Share Price

A listed closed-end fund's shares are worth what someone will pay, and VCX has been worth far more than its portfolio. The fund's own prospectus supplement of September 10, 2026 states it plainly on the cover: the closing price on September 8 was $38.12 and the NAV at the close of business that day was $21.70 per share, a premium of 75.7%. The same page warns that the shares "have traded at prices substantially above their NAV" and that "investors purchasing Common Shares while they are trading at a premium may incur significant losses even if NAV is stable or increases." This was not a late development: the shares first traded on March 19, 2026 at $31.25 and the audited NAV at March 31 was $18.97. The premium was present early in the listing period, but the $31.25 March 19 trading price and the $18.97 March 31 audited NAV are not same-day observations and cannot be used to calculate a first-day premium. USVC has no market premium to pay or lose, because the fund issues its shares at NAV and prices its tender offers on NAV, subject to any applicable repurchase fee.

Price against NAVVCX: $38.12 close against $21.70 NAV on September 8, 2026, a 75.7% premium, both figures from the fund's prospectus supplement. Per market data, $29.62 on September 30 was 36.5% above the last filed NAV of $21.70 from September 8, which is not a same-day premium calculation. USVC: shares are issued at NAV and tenders are priced on NAV, subject to any applicable repurchase fee, so they carry no market premium or discount.
What $10,000 buysVCX: about 262 shares at $38.12, which is roughly $5,693 of net asset value on the September 8 pair; about 338 shares at the September 30 close, roughly $7,326 against that NAV. USVC: $10,000 of net asset value at $22.47, about 445 shares.
Direction of travelVCX fell 22.3% between the September 8 close of $38.12 and the September 30 close of $29.62. No filing in that window reports a NAV change of that magnitude. The lockup on pre-February 20, 2026 shares expired on August 13, a month earlier than originally set, and an at-the-market program for up to $1 billion of new shares began on September 10.
New share issuanceVCX: up to $1,000,000,000 through Jefferies LLC as sales agent, at a minimum price of NAV plus the commission, with the commission up to 3.0% of gross proceeds. Issuing above NAV adds to NAV per share for existing holders and adds supply at the premium. USVC: continuous issuance at NAV, which is neither accretive nor dilutive to NAV per share.
Who sets the markVCX: the market sets the share price daily; the adviser still sets the NAV those shares are measured against, and 72.9% of net assets were Level 3 at June 30, 2026. USVC: the adviser sets the NAV at which every share is both bought and sold, with 63.6% of net assets at Level 3.

Verdict

USVC eliminates secondary-market premium risk at entry. At $38.12 the buyer paid $1.757 for each $1 of reported NAV. If that premium disappeared entirely with NAV unchanged, the share price could fall 43.1%. Conversely, NAV would have to rise 75.7% for a zero-premium share price to equal the $38.12 purchase price. A VCX buyer therefore depends on the premium the market assigns on the day they sell, not only on the portfolio.

A higher management fee that costs less

USVC vs VCX: Fees

The headline fees point one way and the audited ratios point the other. VCX charges 1.85% of average daily net assets, nearly double USVC's 1.00%, and its shareholders rejected a proposed increase to 2.50% at the February 2026 meeting that approved the listing. Yet for the year ended March 31, 2026 VCX reported a gross expense ratio of 2.57% including interest expense, 2.51% excluding it, with no waiver needed because its operating expenses came in under the 3.00% cap in its expense limitation agreement. USVC's July 28, 2026 fee table estimates 4.55% of total annual expenses, built from the 1.00% management fee, a 0.25% shareholder services fee, 0.95% of acquired fund fees and 2.35% of other expenses, and gets to 2.50% only through a 2.05% waiver that runs to November 24, 2027. Scale appears to explain much of the difference: the same kind of fixed cost base spread over $776.97 million looks very different from one spread over $39.35 million, though the two funds also run different underlying expense structures. The two numbers are not like for like either, because VCX's is an audited trailing ratio and USVC's is a forward estimate that holds only while the waiver does.

Management feeVCX: 1.85% of average daily net assets, $6.87 million incurred in the year ended March 31, 2026; a proposed increase to 2.50% was rejected by shareholders in February 2026. USVC: 1.00% of average daily NAV plus a 0.25% shareholder services fee, with no carried interest to the adviser.
Total expense ratioVCX: audited 2.57% gross including interest expense and 2.51% excluding it for the year ended March 31, 2026, with net equal to gross. USVC: 4.55% estimated gross and 2.50% net in the current fee table; the first five-month period ran 17.79% gross and 1.49% net on a $9 million base.
Expense cap and recoupmentVCX: operating expenses capped at 3.00% of average daily net assets, excluding interest, taxes, brokerage, leverage costs, acquired fund fees and extraordinary items, with three-year recoupment. USVC: capped categories limited to 0.30% through November 24, 2027, with $555,135 already waived and recoupable through March 31, 2029.
Fees underneath the fundBoth buy third-party vehicles that charge their own fees, and USVC's table already estimates 0.95% of acquired fund fees while VCX's expense cap excludes acquired fund fees from the capped categories. What neither itemizes is the performance allocation: underlying carried interest may reduce the value ultimately received from a successful vehicle investment without appearing as a separate annual expense-ratio line.
Cost of getting inVCX: no sales load, but the market price carried a 75.7% premium to the fund's same-day NAV on September 8, 2026, and $29.62 on September 30 was 36.5% above the last filed NAV of $21.70 from September 8, which is not a same-day premium calculation. On $10,000 that later figure is about $2,674 of premium, roughly ten times one year of VCX's 2.57% expense ratio as a size comparison rather than an equivalent cost. USVC: no load direct, up to 3% through an intermediary, and shares are issued at NAV.

Verdict

Read the running costs as converging near 2.5% without treating them as the same measurement: VCX's is audited and trailing, USVC's is a forward estimate resting on a waiver that expires in November 2027. Then spend the attention on what neither ratio itemizes, the performance allocation inside the vehicles, and on the premium a VCX buyer pays once at the door.

Same plumbing, very different disclosure

USVC vs VCX: Holdings

Both funds buy private companies the same way, through special purpose vehicles and third-party funds alongside a few direct positions, and the two portfolios overlap at the very top. What separates them is how much the filings tell you. VCX's annual report publishes a top-ten table by economic issuer, naming the company and its percentage of net assets even where the position is held through a vehicle: Anthropic at 16.5%, Databricks at 14.1%, OpenAI at 12.4%, Anduril at 5.5% and Ramp at 4.1% at March 31, 2026. USVC's filed schedule lists the vehicles by their legal names, such as Fund I, a series of Todd and Rahul's Angel Deals, LP, and QP-RE-1229 Fund II, a series of Roll Up Vehicles, LP, and the company names appear only in the shareholder letter's prose without values. An investor who wants to know which company they own, and how much of it, learns more from VCX's filings.

Position count and sizeVCX: 62 holdings on net assets of $776,968,362 at June 30, 2026. USVC: 13 vehicle interests plus one direct position on net assets of $39,348,007 at the same date.
Largest positionVCX: SaxeCap Advisors VIII, LP at $128.2 million, 16.50% of net assets, followed by AI Growth GRT, LLC at 9.33% and Quiet OA Access LP at 8.32%. USVC: Fund I, a series of Todd and Rahul's Angel Deals, LP at $7,572,500, 19.2% of net assets, with Mercury Technologies Series D preferred the only direct holding at 12.7%.
Look-through disclosureVCX: the annual report names the economic issuer and the percentage of net assets for its ten largest investments, and the schedule of investments footnotes which positions are held through vehicles. USVC: the filed schedule names the vehicles; the companies (xAI, Anthropic, OpenAI, Vercel, Crusoe, Sierra, Legora) appear in the shareholder letter without values, and the site's company count is a platform figure rather than a filed one.
Cash and other assetsVCX: 5.37% in a Treasury money market fund and 4.56% in data-center asset-backed securities (Switch, QTS and Vantage securitizations) at June 30, 2026. USVC: 39.0% in a government money market fund at the same date, following $29.5 million of subscriptions in the preceding quarter.
Valuation and leverageVCX: $566.3 million of Level 3 assets, 72.9% of net assets, and $15.879 million of reverse repurchase agreements outstanding at March 31, 2026 with asset coverage of $44,756 per $1,000. USVC: $25.0 million of Level 3 assets, 63.6% of net assets, and no borrowings at June 30, 2026.

Verdict

VCX is the better-documented portfolio and the more concentrated one at the economic-issuer level. USVC is smaller, holds a third of its assets in a money market fund, and does not publish a look-through. Neither is diversified in the sense an index investor would mean.

A certain exit at an uncertain price, or the reverse

USVC vs VCX: Liquidity and Exit

This is the cleanest trade-off on the page. VCX can be sold in any NYSE session, which is a real and unusual advantage for a portfolio that is 72.9% Level 3, but the proceeds depend on what the market is paying relative to NAV that day, and that figure has moved violently: $38.12 on September 8, 2026 and $29.62 on September 30, a fall of 22.3% in three weeks with no filed NAV change of comparable size. USVC cannot be sold to anyone. Its prospectus says the adviser "intends to recommend" quarterly repurchase offers of no more than 5% of net assets and that the board "may decide not to conduct" them, which is a weaker commitment in form than an interval fund's fundamental policy. The mechanism has run twice. The first offer, capped at $2 million, bought every share tendered: 19,379.119 shares at $22.04, about $427,000, or 1.1% of net assets. The second, for up to $2.75 million, expires October 29, 2026.

Exit mechanismVCX: sale on the NYSE at the prevailing market price, any trading day. The fund has no redemption program; its tender offer program ended with the listing. USVC: tender offers only, at NAV, at the board's discretion, prorated if oversubscribed.
Tested capacityVCX: daily exchange volume, with pre-listing shares freed from lockup on August 14, 2026. USVC: one completed offer at 1.1% of net assets against a stated intention of up to 5% per quarter, so the capacity has not been tested by real demand.
Price risk at exitVCX: the premium can compress regardless of NAV, which is what the prospectus supplement warns about and what the September price path shows. USVC: no premium risk, but a 2.00% repurchase fee applies to shares held under a year and is waived only at the board's present discretion.
Supply dynamicsVCX: the at-the-market program can sell up to $1 billion of new shares at or above NAV plus commission, which adds supply while the shares trade above NAV. USVC: continuous issuance at NAV, with the adviser itself holding about 20% of the shares and able to tender alongside everyone else.
What failure looks likeVCX: you sell into a narrower premium or a discount and lose money on a portfolio that gained value. USVC: no offer is made in a given quarter, or the offer is prorated, and you hold a Level 3 portfolio you cannot exit at all.

Verdict

If you need to be able to sell, VCX is the only one of the two that lets you. If you need to know what you will receive when you do sell, USVC's NAV-based tender is the more predictable number, provided an offer is made at all.

$10,000 in each, side by side

 USVC (AngelList)VCX (Fundrise Innovation Fund)
What you buyAbout 445 newly issued shares at the $22.47 NAV of September 29, 2026, which is $10,000 of net asset value. No sales load on usvc.com; $500 minimum.About 338 shares from another investor at the $29.62 close of September 30, 2026, which is roughly $7,326 of net asset value measured against the fund's last filed NAV of $21.70. At the September 8 close of $38.12 it was about $5,693.
Premium paid at the doorNone. Shares are issued at NAV and tenders are priced on NAV, less any repurchase fee in force (currently waived).About $2,674 on the September 30 price against the September 8 NAV, and about $4,307 on the September 8 pair. The smaller of those is close to ten years of VCX's own expense ratio.
Annual cost to youAbout $250 at the 2.50% capped net ratio, rising toward $455 at the 4.55% gross estimate if the waiver is not renewed after November 24, 2027.About $257 at the 2.57% gross ratio reported for the year ended March 31, 2026. No waiver is currently needed to reach it.
When you see the money againOnly when the board offers a tender, at NAV, for up to about 5% of net assets. The first offer took 1.1% of the fund; the second expires October 29, 2026. No distributions were paid in the first period.Any NYSE session, at the prevailing price. Distributions are minimal: the annualized rate was 0.14% at March 31, 2026 and every distribution that year came from capital gain.
Investor tax reportingFund-level reporting rather than a Schedule K-1 from the underlying vehicles. The fund intends to qualify as a regulated investment company and has no C corporation history, so no built-in gains overhang.Fund-level reporting rather than a Schedule K-1. Gains that accrued during the fund's C corporation period are taxable at corporate rates if realized within five years of its regulated investment company election; $3.850 million of deferred tax was accrued in NAV at March 31, 2026.
What actually goes wrongNo offer is made, or it is prorated, and you hold a portfolio that is 63.6% Level 3 with no way to exit. Or the waiver lapses and the ratio moves toward 4.55%.The premium compresses and you lose money while the portfolio gains value. That is what the prospectus supplement warns about, and the price fell 22.3% in the three weeks to September 30, 2026.

Can I buy USVC at NAV instead of paying a premium for VCX?

Short answer

On the fund's own figures, VCX closed at $38.12 on September 8, 2026 against a NAV of $21.70 per share, a 75.7% premium, and the prospectus supplement that discloses both numbers warns that buyers at a premium may incur significant losses even if NAV is stable or increases. USVC issues shares at NAV and prices its tenders on NAV, subject to any applicable repurchase fee, so no market premium arises. That single difference outweighs every fee comparison on this page.

A listed closed-end fund has two prices: the net asset value the adviser calculates, and the market price other investors will pay. Most listed closed-end funds trade below NAV, which is why the standard prospectus warning is about discounts. VCX has done the opposite. The shares first traded at $31.25 on March 19, 2026, and the audited NAV twelve days later was $18.97, which is not a same-day pair but does place a premium early in the listing period. By September 8 the fund reported a same-day pair of $38.12 against $21.70.

The arithmetic matters more than the percentage. At $38.12 the buyer paid $1.757 for each $1 of reported NAV. If that premium disappeared entirely with NAV unchanged, the share price could fall 43.1%. Conversely, NAV would have to rise 75.7% for a zero-premium share price to equal the $38.12 purchase price. Neither outcome is a forecast: the premium could persist, widen or vanish, and a seller realizes whatever it is on their own exit day. For scale, the premium per $10,000 on the September 8 pair was roughly 17 times one year of VCX's 2.57% expense ratio, which is a size comparison rather than an equivalent economic cost, and it is why an 85 basis point difference in management fees is the wrong thing to argue about.

USVC removes that variable and adds a different one. Because the fund issues new shares at the next calculated NAV and prices its tender offers on NAV, an investor never pays or receives a market premium, though a tendering holder receives NAV less any repurchase fee then in force. What they take on instead is the adviser's valuation process with no market to check it against, and a first fiscal year in which the audited NAV of $20.39 at March 31, 2026 sat about 3% above the roughly $19.75 per share implied by the N-PORT for the same date, a difference the annual report attributes to accounting adjustments without reconciling the two.

Which has lower total fees, USVC or VCX?

Short answer

They cost nearly the same to run and the headline fees mislead in both directions. VCX reported an audited 2.57% gross expense ratio for the year ended March 31, 2026 on a 1.85% management fee, with no waiver. USVC charges 1.00% plus a 0.25% servicing fee but estimates 4.55% of total expenses, reaching 2.50% only through a waiver that expires November 24, 2027. The two are not the same measurement: one is a trailing audited ratio, the other a forward estimate dependent on that waiver. Underlying carried interest sits outside both.

Scale is doing the work. A registered fund's audit, administration, custody, legal, compliance, insurance and board costs are largely fixed, so the ratio depends on what they are divided by. VCX divides them across $776.97 million and lands at 2.57% while paying a 1.85% management fee. USVC divides them across $39.35 million and would land at 4.55% without help, which is why the adviser waived $555,135 in the fund's first five months, when the gross ratio annualized to 17.79%.

Both waivers come with strings, and VCX's are looser. Its expense limitation caps operating expenses at 3.00% of average daily net assets, a level its own expenses did not reach, with three-year recoupment. USVC's cap is 0.30% on a narrower set of categories through November 24, 2027, renewable year to year at the adviser's and board's option, with $555,135 already recoupable through March 2029. Permitted recoupment could keep USVC's realized expenses near the cap even as asset growth lowers its underlying operating-cost ratio.

The layer neither fund shows is the one underneath. USVC's table puts acquired fund fees at 0.95% and its prospectus says the vehicles it buys "may charge upfront broker fees as well as management fees and carry." VCX's expense limitation excludes acquired fund fees from the capped categories, and its largest single position at June 30, 2026 was a $128.2 million limited partnership interest. Underlying carried interest is charged on gains at exit, so it reduces the value an investor ultimately receives from a successful vehicle rather than showing up as a separate annual expense-ratio line. USVC's 0.95% estimate covers the vehicles' ongoing fees, not that performance allocation.

Which fund offers better diversification across private companies?

Short answer

VCX holds 62 positions to USVC's 14 and discloses far more about them, naming Anthropic at 16.5%, Databricks at 14.1% and OpenAI at 12.4% of net assets in its annual report. But it is not less concentrated: those five largest economic issuers were 52.6% of the fund. USVC's largest position was 19.2%, and 39.0% of its net assets sat in a money market fund. Both carry most of the portfolio at Level 3.

The two portfolios are built the same way. Both buy limited partnership and LLC interests in special purpose vehicles and third-party funds, both hold a few positions directly, and both value nearly everything with the adviser as valuation designee under Rule 2a-5. At June 30, 2026 VCX carried $566.3 million at Level 3, 72.9% of net assets, and USVC carried $25.0 million, 63.6%.

Where they differ is what an investor can verify. VCX's annual report publishes a top-ten table by economic issuer with values and percentages, and footnotes which of those positions are held through vehicles whose sole underlying investment is the named company. Its quarterly holdings report lists the vehicles themselves, including SaxeCap Advisors VIII, AI Growth GRT, Quiet OA Access and AI Access 12, alongside directly held names such as Databricks, Epic Games, Ramp, Fivetran, Vanta, Figure AI and Canva. USVC's filed schedule names only the vehicles, and the companies appear in the shareholder letter as a list without values.

That makes the overlap easy to see and impossible to size. VCX's two largest economic exposures are Anthropic and OpenAI. USVC's shareholder letter names exposure to xAI, Anthropic, OpenAI, Vercel, Crusoe, Sierra and Legora, without weights. An investor holding both funds owns at least those two companies through both, at two different prices relative to net asset value, and cannot measure the duplication from USVC's filings.

The AltStreet Take

This is the rare comparison where the weaker fund has the stronger argument. Everything institutional about the Fundrise Innovation Fund is better: three years of audited operations against five months, $776.97 million against $39.35 million, 62 positions against 14, a named and sized look-through, a KPMG opinion, a lower audited expense ratio, and an exchange listing that lets a holder leave on any trading day. USVC is a young fund whose first fiscal year was almost entirely its own adviser's money and whose adviser had never run a registered fund.

And yet the entry price is the term that dominates the outcome. A fund trading at $38.12 for $21.70 of portfolio is asking a buyer to pay for 75.7% of appreciation that has not happened. The fund says so itself, on the cover of a prospectus supplement, while simultaneously registering up to $1 billion of new shares to sell into that premium through Jefferies. Nothing in that is improper. It is what a listed fund does when its shares are expensive, and it is also supply arriving at exactly the price level a new buyer is paying.

The sequence worth watching is already on the record. The lockup on pre-listing shares was accelerated by a month to August 13, 2026. The at-the-market program started September 10. Between September 8 and September 30 the price fell from $38.12 to $29.62, a 22.3% decline, with no filed NAV change of that size. AltStreet is not claiming the float and the issuance caused the fall. It is pointing out that a premium is a market's opinion rather than a portfolio value, and that opinions about scarce supply change when the supply stops being scarce. Check the premium on the day you buy, not the one in this guide.

Can I sell my investment more easily with VCX or USVC?

Short answer

VCX, by a wide margin, because it trades on the NYSE and USVC has no market at all. USVC's only exit is a quarterly tender offer the adviser intends to recommend and the board may decline; the first one repurchased 1.1% of net assets. The catch is symmetrical: VCX guarantees you can sell and guarantees nothing about the price, and that price fell 22.3% in the three weeks to September 30, 2026.

USVC is a tender offer fund rather than an interval fund, a distinction that matters precisely here. An interval fund operating under Rule 23c-3 commits to a repurchase schedule that only a shareholder vote can change. USVC obtained relief from that rule in the SEC's February 18, 2026 exemptive order, and its prospectus says the adviser "intends to recommend" quarterly offers of no more than 5% of net assets while the board "may decide not to conduct" them. Two offers have run. The first bought every share tendered, 19,379.119 shares at $22.04, about $427,000, well inside its $2 million cap, so the 5% capacity has never been tested against real demand.

VCX used to work the same way and stopped. It operated as a tender offer fund from July 2022, filing a Schedule TO roughly every quarter, until shareholders approved the NYSE listing on February 19, 2026. The exchange replaced the tender program entirely, which is why the fund now has no redemption mechanism: a seller finds a buyer at a market price instead of asking the fund for cash at NAV.

Those are genuinely different risks rather than more or less of the same one. A USVC holder faces the possibility of being unable to sell for a quarter or several, and knows roughly what they would receive if an offer comes. A VCX holder can always sell and cannot know what they will get, because the premium is an independent variable: the holdings could appreciate while the share price falls, which is the configuration the September data show.

Which has the stronger record, and which is cleaner on tax?

Short answer

VCX has three years of audited operations and a 68.39% NAV return for the year ended March 31, 2026, with 19.45% annualized since its July 2022 inception. USVC has one audited period of five months that returned 1.95% on a GAAP NAV while 92% of the fund was the adviser's own seed capital. On tax, USVC is the cleaner structure: VCX carries a five-year built-in gains exposure from its C corporation years, with $3.850 million of deferred tax already accrued in NAV.

Read VCX's return table with one caution. The NAV figures are what they appear to be: 68.39% for the year to March 31, 2026 and 19.45% annualized since July 25, 2022, against 24.81% and 17.86% for the NASDAQ Composite over the same periods. The market price line in the same table shows 319.04% since inception, which the report's own footnote explains is computed from March 19 to March 31, 2026, thirteen days of trading. That figure is an annualization artifact rather than a return anyone earned, and it should not be carried into any comparison.

USVC's record is too short to compare. Its only audited period ran from November 3, 2025 to March 31, 2026 and produced a 1.95% total return on a GAAP net asset value, during which the adviser's 405,000 shares were about 92% of the fund. Public subscriptions arrived only after the April 22, 2026 launch: $1.83 million in April, $17.58 million in May and $10.07 million in June. The transaction NAV has moved from $20.00 at launch to $22.47 on September 29, 2026, most of it in July, on a book that was largely carried at cost.

The tax comparison runs the other way. VCX elected regulated investment company status for its taxable year ended March 31, 2026 after three and a half years as a C corporation, and gains that accrued in those years are taxable at corporate rates if realized within five years of the election. The fund has already accrued the liability inside its NAV, $3.850 million net at March 31, 2026, and remeasures it quarterly. USVC intends to qualify as a regulated investment company with no C corporation history behind it, so there is no equivalent drag on its most appreciated positions. Both are fund-level structures rather than partnership interests, so neither passes a Schedule K-1 from the underlying vehicles through to shareholders.

Frequently asked questions

Is USVC a better investment than Fundrise VCX?+

They are not the same trade, so the answer turns on price and patience rather than quality. VCX is the larger, older, cheaper-to-run fund: $776.97 million of net assets at June 30, 2026, three years of operating history, an audited 2.57% expense ratio and daily NYSE liquidity. USVC is five audited months old, held $39.35 million at the same date, and its first fiscal year was 92% the adviser's own seed money. What offsets all of that is the entry price. VCX's own September 10, 2026 prospectus supplement reports a September 8 closing price of $38.12 against a NAV of $21.70 per share, a 75.7% premium, and warns that buyers at a premium "may incur significant losses even if NAV is stable or increases." USVC sells shares at NAV. If you want the bigger and better-documented portfolio and will accept paying more than the portfolio is carried at, VCX. If you refuse to pay a premium and can wait for a tender offer the board is not obliged to make, USVC.

How do USVC and the Fundrise Innovation Fund differ?+

Both are non-diversified closed-end funds registered under the Investment Company Act of 1940, both are open to any US investor, and both reach private technology companies partly through special purpose vehicles and partly through direct positions. The difference is how shares are priced and sold. The Fundrise Innovation Fund converted from a tender offer fund to a listed fund and began trading on the NYSE as VCX on March 19, 2026 at $31.25 per share; shares now change hands between investors at whatever price the market sets. USVC Venture Capital Access Fund is continuously offered by the fund itself at the next calculated NAV, $500 minimum, with no sales load on usvc.com, and the only exit is a quarterly tender offer the adviser intends to recommend and the board may decline to make.

Can I buy USVC at NAV instead of paying a premium for VCX?+

Yes, and that is the clearest practical reason the comparison exists. USVC issues new shares at the next calculated NAV, which was $22.47 on September 29, 2026, with no load when bought directly. VCX shares are bought from other investors on the NYSE, so you pay the market price. On September 8, 2026 that price was $38.12 against a stated NAV of $21.70, both figures from the cover of the fund's own prospectus supplement. On those two numbers, $10,000 buys about $5,693 of VCX net asset value and $10,000 of USVC net asset value. The premium has moved a great deal: per market data, $29.62 on September 30 was 36.5% above the last filed NAV of $21.70 from September 8, which is not a same-day premium calculation, which works out to about $7,326 of NAV per $10,000.

Which has lower total fees, USVC or VCX?+

On the audited numbers, VCX, and by less than the management fees suggest. VCX charges a 1.85% management fee and reported an audited 2.57% gross expense ratio including interest expense for the year ended March 31, 2026, with no waiver needed. USVC charges a 1.00% management fee plus a 0.25% shareholder services fee, and its July 28, 2026 fee table estimates 4.55% of total annual expenses reduced to 2.50% by a waiver that runs to November 24, 2027. So the running costs converge near 2.5% even though USVC's management fee is 85 basis points lower, and the two figures are not directly comparable: VCX's 2.57% is an audited trailing ratio and USVC's 2.50% is a prospectus estimate that depends on a waiver. Scale appears to explain much of the gap, since VCX spreads its fixed costs over $776.97 million and USVC over $39.35 million. Underlying carried interest sits outside both and may reduce what an investor ultimately receives from a successful vehicle without appearing as a separate annual expense-ratio line. The cost that actually separates them is not annual at all. It is the premium a VCX buyer pays on entry, roughly 17 times one year of VCX's expense ratio on the September 8 figures.

Which fund offers better diversification across private companies?+

VCX holds more names and more of them are disclosed, but it is not less concentrated at the top. At June 30, 2026 VCX held 62 positions against USVC's 13 vehicle interests plus one direct holding. VCX's largest single position was 16.50% of net assets (SaxeCap Advisors VIII, LP); USVC's was 19.2% (Fund I, a series of Todd and Rahul's Angel Deals, LP). Looked through to the economic issuer, VCX's March 31, 2026 annual report put Anthropic at 16.5%, Databricks at 14.1%, OpenAI at 12.4%, Anduril at 5.5% and Ramp at 4.1%, so five companies were 52.6% of the fund. USVC held 39.0% of net assets in a government money market fund at June 30, which is cash rather than diversification. Both carry most of their portfolios at Level 3: 72.9% of net assets for VCX, 63.6% for USVC.

Can I sell my investment more easily with VCX or USVC?+

VCX, without qualification, but the certainty you gain is about timing rather than value. VCX trades on the NYSE every session, so you can sell on any trading day at whatever premium or discount the market is paying. Between September 8 and September 30, 2026 the price fell from $38.12 to $29.62, a decline of 22.3% over three weeks, and no filing in that window indicates a NAV move of that size. USVC has no secondary market. Its prospectus says the adviser intends to recommend quarterly repurchase offers of no more than 5% of net assets and that the board "may decide not to conduct" them. The first offer bought 19,379.119 shares at $22.04, about $427,000, or 1.1% of the fund. VCX offers a certain exit at an uncertain price; USVC offers a price you can predict, at a time you cannot.

Does USVC's "no performance fees" claim include its underlying funds?+

No, and the same caveat applies to VCX. USVC pays its adviser no carried interest, which is what the site's "No performance fees" line refers to. Its prospectus says the special purpose vehicles it buys "may charge upfront broker fees as well as management fees and carry," and the fee table folds the vehicles' fees into a 0.95% acquired fund fees and expenses estimate. Carried interest on a venture vehicle is typically taken at exit, so it reduces the value ultimately received from a successful investment rather than appearing as an annual expense-ratio line. VCX is in the same position: its expense limitation agreement explicitly excludes acquired fund fees and expenses from the capped categories, and it holds large positions in third-party limited partnerships. Neither fund's headline cost itemizes what the layer underneath charges on gains, even though USVC's table does include 0.95% for the vehicles' ongoing fees.

Is USVC an interval fund or a tender offer fund?+

A tender offer fund, and VCX used to be one before it listed. USVC has no fundamental repurchase policy under Rule 23c-3; the SEC's February 18, 2026 exemptive order relieved it from that rule, and liquidity rests on discretionary offers the board may decline. An interval fund, by contrast, commits to a repurchase schedule that only shareholders can change. The Fundrise Innovation Fund operated as a tender offer fund from July 2022 until its shareholders approved a NYSE listing on February 19, 2026; its last tender offer was filed in early 2026 and it now has no redemption program at all, because the exchange supplies the exit.

Why did VCX trade so far above its NAV?+

The filings show a listing into a restricted float. VCX began NYSE trading on March 19, 2026 at $31.25 per share, and its audited NAV at March 31, 2026 was $18.97. Those observations are twelve days apart, so they do not establish a first-day premium; what they do show is that a premium was present early in the listing period. All shares bought before February 20, 2026 were locked up. On July 24, 2026 the fund announced it was accelerating that lockup's expiry from September 14 to August 13, 2026, making those shares tradable on August 14. On September 9 and 10 the fund filed a shelf registration and a prospectus supplement for an at-the-market program of up to $1 billion of new shares through Jefferies LLC, priced at no less than NAV plus commission. More supply reaching a market that had been paying a large premium is the context in which the price fell from $38.12 on September 8 to $29.62 on September 30. AltStreet is describing a sequence, not establishing a cause.

Does holding both USVC and VCX diversify anything?+

Less than the two names suggest, because the portfolios overlap at the top. VCX's annual report identifies Anthropic and OpenAI as its largest and third-largest economic exposures. USVC's first shareholder letter lists exposure to "xAI (acquired by SpaceX), Anthropic, OpenAI, Vercel, Crusoe, Sierra, and Legora." The portfolios therefore overlap in at least Anthropic and OpenAI, but USVC does not disclose look-through weights, so the economic significance of that overlap cannot be quantified from its filings. The genuine differences are structural rather than sectoral: VCX adds data-center asset-backed securities, 4.6% of net assets at June 30, and uses modest leverage through reverse repurchase agreements, $15.879 million outstanding at March 31, 2026, while USVC held no borrowings and 39.0% cash equivalents. Owning both mostly doubles the same private artificial intelligence exposure at two different prices relative to NAV.

Can I buy either fund in an IRA?+

Both are plausible in a retirement account and neither raises the collectibles problem that applies to physical assets. VCX is an NYSE-listed security, so any brokerage IRA can hold it. USVC is sold directly and through intermediaries including SoFi, and whether a particular custodian will hold an unlisted closed-end fund is a question for that custodian. The tax points that actually differ are at the fund level. VCX elected regulated investment company status for its taxable year ended March 31, 2026 after three and a half years as a C corporation, and gains that accrued during the C corporation period remain subject to tax at corporate rates if realized within five years of the election; the fund has already accrued a deferred tax liability, $3.850 million net at March 31, 2026, inside its NAV. USVC has no C corporation history and no equivalent overhang. Both are fund-level structures rather than partnership interests held directly by the investor, so neither passes a Schedule K-1 from the underlying vehicles through to shareholders. Confirm your own position with a tax adviser.

Related records on AltStreet

Disclosures:AltStreet has no commercial relationship with AngelList, AngelList Asset Management, LLC, USVC Venture Capital Access Fund, Fundrise, Rise Companies Corp, Fundrise Advisors, LLC or Fundrise Innovation Fund, LLC, holds no shares of either fund, and received no compensation for this comparison. VCX figures are from SEC EDGAR filings of Fundrise Innovation Fund, LLC (CIK 1867090): the annual report on Form N-CSR for the year ended March 31, 2026 (accession 0001435109-26-000093) and its amendment, the Form N-PORT holdings report for June 30, 2026 (accession 0001867090-26-000109), the automatic shelf registration of September 9, 2026 and the Rule 424(b)(2) prospectus supplement of September 10, 2026 (accession 0001213900-26-098534), and the Form 8-K of July 27, 2026 reporting the accelerated lockup expiry (accession 0001213900-26-081869). USVC figures are from the filings of USVC Venture Capital Access Fund (CIK 1858660): the annual report on Form N-CSR for the period ended March 31, 2026 (accession 0001104659-26-071224), the Form N-PORT for June 30, 2026 (accession 0001193125-26-373847), the post-effective amendment and prospectus of July 28, 2026 (accession 0001999371-26-016261), and the tender offer statements of June 30 and September 30, 2026 with the September 10 results amendment. The VCX share price of $29.62 is market data as of the September 30, 2026 close and is not a filed figure; the $21.70 NAV it is measured against is the fund's last NAV disclosed in a filing, dated September 8, 2026, so the 36.5% implied by that pair is an approximation across two dates rather than a same-day premium. The $31.25 first trading price of March 19, 2026 and the $18.97 audited NAV of March 31, 2026 are likewise twelve days apart and are not used here to compute a first-day premium. The USVC NAV of $22.47 is the fund's published daily net asset value for September 29, 2026. Dollar scenarios are arithmetic on the cited figures and exclude brokerage commissions and taxes. Return figures are historical and do not guarantee future results. This is not investment advice. AltStreet rating systems are proprietary and not universal standards. All investors should consult a qualified financial adviser before making investment decisions.

Last updated: October 1, 2026 · https://altstreet.investments/guides/usvc-vs-fundrise-vcx